CD274 and cancer: Given the significant advancements in cancer immunotherapy, particularly the use of anti-PD-L1 antibodies[41], we further investigated the predictive role of the dysregulated palmitoylation in ICI-treated cancer cohorts, specifically focusing on patients with urological tumors.